+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Tri-monthly intravenous injections of ibandronate for treatment of postmenopausal osteoporosis



Tri-monthly intravenous injections of ibandronate for treatment of postmenopausal osteoporosis



Journal of Bone & Mineral Research 16(Suppl 1): S406




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035985791

Download citation: RISBibTeXText


Related references

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. American Journal of Medicine 103(4): 298-307, 1997

Treatment of corticoid-induced osteoporosis by 3-monthly intravenous ibandronate injections. Journal of Bone & Mineral Research 15(Suppl 1): S150, 2000

Intravenous injections of ibandronate (IB) in the treatment of postmenopausal osteoporosis. Osteoporosis International 6(1 Suppl.): 94-94, 1996

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis. Osteoporosis International 26(11): 2685-2693, 2015

Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis and Rheumatism 54(6): 1838-1846, 2006

Efficacy of Intravenous Ibandronate Injections in Postmenopausal Osteoporosis: DIVA 2-Year Findings. Journal of Clinical Densitometry 9(2): 247-248, 2006

Safety and effectiveness of monthly intravenous ibandronate injections in a prospective, postmarketing, and observational study in Japanese patients with osteoporosis. Osteoporosis and Sarcopenia 4(1): 22-28, 2018

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34(5): 890-899, 2004

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Therapeutics and Clinical Risk Management 2(1): 3, 2006

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Journal of Rheumatology 35(3): 488-497, 2008

Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment. Women's Health 2(3): 341-349, 2006

Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone 46(3): 660-665, 2010

Quarterly intravenous ibandronate injections provide continuing benefits in women with postmenopausal osteoporosis: DIVA study long-term extension. 2007

Increase by 10% of spine bone mineral density and effect on bone markers of three monthly intravenous injections of ibandronate in osteoporosis in men with Klinefelters syndrome. Journal of Bone & Mineral Research 15(Suppl 1): S226, 2000

Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study. Journal of Bone and Mineral Metabolism 35(1): 58-64, 2017